Mycoplasma Testing Market Size Worth USD 2.18 Billion by 2030 at 13.9% CAGR – Report by Market Research Future (MRFR)

Mycoplasma Testing Market Trends and Insights by Product (Kits & Reagents, Instruments, Services), Technique (DNA, PCR, ELISA, Direct, Indirect Assay), Application (cell line testing, virus testing), End user (CRO, Cell banks), Competitive Market Growth, Size, Share and Forecast to 2030

New York, USA, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Mycoplasma Testing Market Overview:

According to a Comprehensive Research Report by Market Research Future (MRFR), “Mycoplasma Testing Market Information By Product, Technique, Application, End use - Forecast till 2030, the market is expected to be worth USD 2.18 billion by 2030 at CAGR of 13.9% during the forecast period 2022-2030.

Mycoplasma Testing Market Scope:

Mycoplasma testing is essentially a medical testing method performed by medical professionals to assist you in promptly detecting or ruling out mycoplasma contamination of your cell cultures. This approach consists of a set of tests that either assess antibodies in the blood produced in response to a mycoplasma infection or directly detect the organism through culture or detection of its genetic material (DNA) in a bodily sample.

Contamination with Mycoplasma is a common and recurring issue in many cell culture methods used in life science research and the pharmaceutical business. In culture media, Mycoplasmas can grow to high titers without presenting conventional bacterial contamination indicators such as turbidity. They cause altered metabolism, decreased proliferation, and chromosomal abnormalities in cultured cells. In brief, Mycoplasma contamination jeopardizes the authenticity of impacted cell lines' data as well as the findings of life science research. As a result, Mycoplasma testing and consequently the maintenance of contamination-free cell cultures are critical to cell-based research and the production of commodities where consumer health is a major concern.

Get Free Sample PDF Brochure @

Report Scope:

Report AttributeDetails
Market Size in 2030USD 2.18 Billion
Base Year2021
Forecast Period2022-2030
Historical Data2020
Forecast UnitsValue (USD Billion)
Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered By Product, Technique, Application and End User
Geographies CoveredNorth America, Europe, Asia-Pacific and Rest of the World (RoW)
Key Market DriversGrowing concerns over cell culture contamination
Increasing R&D expense and new product launches

Mycoplasma Testing Market Competitive Dynamics:

  • Charles River Laboratories, Inc.
  • Merck KGaA
  • Lonza Group Ltd
  • Roche Diagnostics
  • SGS S.A.
  • American Type Culture Collection
  • Invivogen
  • Wuxi Apptec
  • Thermo Fisher Scientific Inc.
  • Promocell GmbH

Mycoplasma Testing Market Dynamics:

Market Drivers

The important factors driving the growth of the mycoplasma testing market in the aforementioned projected period include the rising demand for mycoplasma testing, emerging markets, and increasing pharmaceutical outsourcing. Additionally, the market's overall expansion is accelerated by rising cell-line contamination and research and development in biological sciences. The market's overall growth is anticipated to increase due to growing worries regarding cell culture contamination.

Testing for mycoplasma is done to look for contamination in biological samples. It is anticipated that rising R&D expenses and the introduction of new products will fuel the expansion of the mycoplasma testing market. The main benefits of outsourcing clinical trials and R&D for pharmaceutical and biopharmaceutical businesses include cost effectiveness, ease of patient recruitment, lower operating expenses, and less severe regulatory frameworks than in the US and Western Europe. Sponsors who outsource their business operations to CROs, CDMOs, and CMOs do so in part because doing so lowers costs and speeds up time to market. Therefore, a lot of pharmaceutical, biotechnology, and academic institutions choose to outsource activities including production, clinical trial management, research and development, and drug discovery to CROs.

Market Limitations

The market for mycoplasma testing will, however, be constrained in its expansion over the projected period by the availability of substitute conventional procedures.

Browse In-depth Market Research Report (100 Pages) on Mycoplasma Testing:

COVID-19 Analysis:

Recent publications have informed medical professionals that patients with COVID-19 may also be infected with other infections, like Mycoplasma pneumoniae. This indicates that mycoplasma testing is necessary for patients who have COVID-19 signs of pneumonia. It is anticipated that examples like these would increase demand for mycoplasma testing in diagnostic and pathological settings. In various nations throughout the world, the increased rate of coinfections in COVID-19 patients, with a high likelihood that they were brought on by Mycoplasma pneumonia, is anticipated to increase demand for mycoplasma diagnostics in the upcoming months.

Mycoplasma Testing Market Segmentation:

By Product

Based on product and service, the mycoplasma testing market is divided into assays, kits, and reagents; instruments; and services. Assays, kits, and reagents had the highest proportion of this market in 2019. The expansion of this market segment is primarily being driven by the frequent procurement of these consumables compared to instruments and the expanding usage of kit-based approaches for mycoplasma testing.

By Technique

The COVID-19 pandemic gave the PCR market a significant boost, and it is expected to grow over the review period.

By Application

The largest share of this market was held by the cell line testing sector. The expansion of this market segment is fueled by elements including the biopharmaceutical sector's rapid expansion and the rising need for monoclonal antibodies.


The CRO segment is expected to drive the market over the review period.

Buy Now:

Mycoplasma Testing Market Regional Analysis:

Due to a well-established player and rising R&D costs, the Americas are predicted to dominate the mycoplasma testing market on a global scale. The market for mycoplasma testing on a global scale was dominated by North America. The expansion of the biotechnology and pharmaceutical sectors, the high rate of novel technology adoption, and the substantial amount of life science research studies carried out in this region are the main causes of the huge share of this regional category. Due to increased healthcare costs and U.S. government investments to support research-based activities in the biopharmaceutical industry, North America dominated the global market for mycoplasma testing. Additionally expanding in North America is the biopharmaceutical industry, which uses highly purified cultures to create medications.

The second-largest market for mycoplasma testing is anticipated to be in Europe. This region's market expansion is linked to the expansion of the pharmaceutical and medical device industries.

Share your Queries @

Over the projection period, profitable growth is anticipated in the Asia Pacific region. This is as a result of the enormous investment and awareness campaigns launched by nations like India. The Indian government is implementing a number of strategic efforts to encourage more R&D for the development of new medications. Furthermore, it is anticipated that in the near future, development chances would increase as a result of regulatory policies implemented by healthcare organizations in support of enhancements in biosafety quality.

Discover more research Reports on Healthcare Industry, by Market Research Future:

Respiratory Care Devices Market: Therapeutic devices (PAP Devices), Monitoring devices (Pulse Oximeters), Diagnostic devices (Spirometers), Accessories & Consumables (Disposable Masks), and Application (Asthma and Others)- Forecast till 2027

Healthcare Cloud Computing Market Research Report: By Applications (Non-Clinical Information System, Clinical Information System), By Deployment (Private Cloud, Public Cloud, Hybrid Cloud), By End-User (Healthcare Providers, Healthcare Players) and By Service (IaaS, SaaS, PaaS) – Forecast to 2027

Oral Care Market Information By Product (Toothbrush, Toothpaste, Mouthwash, Others) By Distribution Channel (Store-based, Non-store based)- Forecast 2027

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Follow Us: LinkedIn | Twitter


Contact Data